REG - Aptamer Group PLC - Major top 3 global pharma contract win

AptamerAnnouncement

Wed 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251008:nRSH5329Ca&default-theme=true

RNS Number : 5329C  Aptamer Group PLC  08 October 2025

 

8 October 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

  Major top 3 global pharma contract win

£360,000 contract signed for radiopharmaceutical development

£665,000 of additional contract value in recently signed agreements,
£315,000 of smaller deals

 

Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic
binders for the life sciences industry, is pleased to announce a major new
development contract with a top 3 global pharmaceutical company and continued
strong commercial progress in the first quarter of the financial year.

 

The new £360,000 fee-for-service development contract is to develop Optimer®
binders as targeted radiopharmaceuticals with potential applications in
therapeutics. Aptamer retains rights for future licensing revenues upon
commercialisation, positioning the Company for future downstream licensing
and/or royalty revenue streams.

 

This programme will engineer Optimers targeting an undisclosed cancer target.
Preliminary work will develop tools for Positron Emission Tomography (PET)
imaging with a view to translating to therapeutic applications. The Optimer®
platform offers advantages for this application area, including enhanced
tumour penetration, reduced immunogenicity, and ease of chemical optimisation.
The contract expands the application of the Company's Optimer® technology
into the growing targeted radiopharmaceuticals market, valued at $7.5 billion
in 2025, and represents the second therapeutic modality under development by
Aptamer alongside targeted gene therapy.

 

Commercial update

 

Building on the £1.2 million revenue achieved in FY25, the Company has
already secured £315,000 in new contracts and project extensions for the
current financial year. These developments further position the Company for
revenue growth in the current year.

 

Including the new development contract for radiopharmaceutical development,
Aptamer has secured additional commitments totalling £675,000 in total
contract value. Combined with £350,000 of contract value carried over from
FY25, this provides visibility of approximately £1.03 million in contract
value for the current period, with nine months of the year remaining.

 

Aptamer's sales pipeline remains robust and healthy, now standing at £3.4
million for fee-for-service opportunities following the closure of the
£675,000 in new deals and subsequent replenishment through active prospects.

 

The £315,000 in further contracts and extensions signed in this financial
year to date include:

·      Two extensions with a top 5 global pharmaceutical company for
work on an ELISA project.

·      The synthesis of a bulk amount of an enzyme inhibitor to support
a licensing deal under negotiation.

·      A therapeutic development agreement with Invizius to develop
Optimer® binders targeting complement system components for safer treatments
for inflammatory conditions.

·      A range of smaller contracts across therapeutics, diagnostics,
and research, further diversifying the Company's revenue streams.

 

This is not indicative of full-year performance, and the Company is not
providing formal guidance for FY26 at this time as contract timings, project
completions, and revenue recognition can vary significantly across quarters
due to the nature of Aptamer's business.

 

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, said: "This
significant contract win with a top 3 global pharmaceutical company marks a
key expansion of our platform into targeted radiopharmaceuticals and potential
therapeutics.  This represents a value inflection point as Aptamer now has
two potential therapeutic assets under development.

 

"In addition to the smaller contracts and our therapeutic agreement with
Invizius, Aptamer has an order book carried over from FY25, which provides
£1.03 million in contract value visibility alongside our £3.4 million sales
pipeline, providing a strong platform for FY26."

 

-Ends -

 

For further information, please contact: 

 

 Aptamer Group plc                                                  +44 (0) 1904 217 404  

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser                +44 (0) 20 3368 3550  

 Andrew Emmott
 Turner Pope Investments (TPI) Limited - Broker                     +44 (0) 20 3657 0050  

 James Pope / Andrew Thacker  
 Northstar Communications Limited - Investor Relations              +44 (0) 113 730 3896

 Sarah Hollins 

 

About Aptamer Group

 

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group develops
Optimer® binders, advanced molecules that work like antibodies by attaching
to specific targets in the body. These binders are used in medicine,
diagnostic tests, and research tools, offering benefits like high stability,
reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners, aiming
for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email, go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTGUBDGGUGDGUI